ML141

ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7) . ML141 do not show cytotoxicity in multiple cell lines[1][2].

Product Specifications

CAS Number

[71203-35-5]

Product Name Alternative

CID-2950007

UNSPSC

12352005

Hazard Statement

H302, H315, H320, H335

Target

Apoptosis; Ras

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ML141.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=CC=C(N2N=C(C3=CC=CC=C3)CC2C4=CC=C(OC)C=C4)C=C1)(N)=O

Molecular Formula

C22H21N3O3S

Molecular Weight

407.49

Precautions

H302, H315, H320, H335

References & Citations

[1]Hong L, et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013 Mar 22;288 (12) :8531-43.|[2]Surviladze Z, et al. A Potent and Selective Inhibitor of Cdc42 GTPase. Probe Reports from the NIH Molecular Libraries Program|[3]Hanin G, et al. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23 (17) :4569-80.